Clearant Initiates Direct Sales Strategy, Enters Supplier Agreement; Clearant Becomes Exclusive Distributor of Hard Tissue Transplant Materials in Six Markets.

LOS ANGELES -- Clearant, Inc. (OTCBB:CLRI) today announced that the Company has entered into an agreement whereby it will have access to spinal allografts as a processor's representative to accelerate demand for tissue treated with the Clearant Process(R). Clearant will be the exclusive provider for this tissue processor of spinal allografts in selected U.S. markets. The first products to be released under this program will be cervical allografts used in spinal surgery.

The Clearant Process reduces all types of pathogens in the tissue allografts while maintaining a high degree of the underlying protein. Products processed with the Clearant Process can achieve, and even exceed, levels of sterility associated with medical devices.

"Clearant's refined business strategy is designed to promote access to tissue sterilized with the Clearant Process," commented Alain Delongchamp, chief executive officer of Clearant. "By establishing a direct sales force, we are able to better meet the increasing demand by surgeons for tissue safeguarded by the Clearant Process."

To date, more than 8,000 patients have received allograft implants treated with the Clearant Process. Recent data compiled by a consortium of surgeons using the Clearant Process show that following extensive post-operative examinations, knees reconstructed with allografts treated with the Clearant Process demonstrated comparable strength and functionality to the patients' non-operated knee, and to knees reconstructed with conventional allografts.

Clearant will host an investment-community conference call on Tuesday, May 9, 2006, beginning at 11:00 a.m. Eastern time (8:00 a.m. Pacific time) to discuss its new sales and marketing strategy. Individuals interested in listening to the live conference call may do so by dialing 888-443-9985 toll free within the U.S. and Canada, or 706-679-4718 for international callers. To access the slide presentation, please visit the "Investors" section of the Company's Web site at www.clearant.com. A telephone replay of the conference call will be available for 48 hours beginning May 9 within two hours after the conclusion of the call, by dialing 800-642-1687 domestically or 706-645-9291 internationally, and entering reservation number 8664783. Individuals interested in listening to the conference call via the Internet may do so by visiting www.clearant.com. A replay will be available on the Company's Web site for 30 days.

About Clearant, Inc.

Clearant, Inc. is a leader in pathogen inactivation for biological products. Clearant has developed the patent-protected Clearant Process, which substantially reduces all types of pathogens in biological products while maintaining the integrity of underlying protein. Whereas various competing sterilization methods only kill specific types of pathogens (such as bacteria or lipid-enveloped viruses) for specific products, the Clearant Process reduces all types of pathogens for products across many market segments including tissue implants, plasma proteins, recombinant products, medical devices and blood products. Also, the Clearant Process can be applied at various stages of product processing and/or manufacturing, including in the final packaging. For more information, please visit www.clearant.com.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995, in particular statements regarding surgeons strongly recommending the use of implants with tissue treated by the CLEARANT PROCESS, and the conclusions from a study by surgeons to build demand for sterilized tissue. These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control, which may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, results of additional clinical studies, efficacy of the technology, intense competition and substantial regulation in the biotechnology industry, and additional risks discussed in the company's filings with the SEC, available on the SEC web site http://www.sec.gov.